
Please try another search
Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancers in the United States. The company’s lead product candidate is elraglusib injection, a glycogen synthase kinase-3 inhibitor that is in Phase 2 trial to treat metastatic pancreatic ductal adenocarcinoma. It also develops elraglusib, which is in Phase 1/2 trial for the treatment of refractory pediatric malignancies, including Ewing sarcoma, as well as metastatic melanoma and colorectal cancer. The company was formerly known as Apotheca Therapeutics, Inc. and changed its name to Actuate Therapeutics, Inc. in October 2015. Actuate Therapeutics, Inc. was incorporated in 2015 and is headquartered in Fort Worth, Texas.
Name | Age | Since | Title |
---|---|---|---|
Daniel M. Schmitt | 62 | 2015 | CEO, President & Director |
Aaron Glenn Louis Fletcher | 44 | 2015 | Independent Chairman |
Roger B. Cohen | - | 2022 | Member of Scientific Advisory Board |
John Lindsay Marshall | - | 2022 | Member of Scientific Advisory Board |
Daniel L. Zabrowski | 65 | 2021 | Independent Director |
Roger A. Sawhney | 54 | - | Independent Director |
Daniel Billadeau | - | - | Member of Scientific Advisory Board |
Lee M. Ellis | - | 2022 | Member of Scientific Advisory Board |
Jason A. Keyes | 53 | - | Independent Director |
Patricia LoRusso | - | 2022 | Member of Scientific Advisory Board |
Todd S. Thomson | 63 | 2022 | Independent Director |
Amy Lynn Ronneberg | 50 | - | Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review